These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

272 related items for PubMed ID: 22525916

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. [Peroral hormonal contraception and risk of venous thromboembolism].
    Ludka O, Spinar J, Musil V, Pozdísek Z.
    Vnitr Lek; 2010 May; 56(5):370-5. PubMed ID: 20578585
    [Abstract] [Full Text] [Related]

  • 23. Venous thromboembolism in women taking hormonal contraceptives.
    Blanco-Molina A, Monreal M.
    Expert Rev Cardiovasc Ther; 2010 Feb; 8(2):211-5. PubMed ID: 20136607
    [Abstract] [Full Text] [Related]

  • 24. Statement on combined hormonal contraceptives containing third- or fourth-generation progestogens or cyproterone acetate, and the associated risk of thromboembolism.
    Bitzer J, Amy JJ, Beerthuizen R, Birkhäuser M, Bombas T, Creinin M, Darney PD, Vicente LF, Gemzell-Danielsson K, Imthurn B, Jensen JT, Kaunitz AM, Kubba A, Lech MM, Mansour D, Merki G, Rabe T, Sedlecki K, Serfaty D, Seydoux J, Shulman LP, Sitruk-Ware R, Skouby SO, Szarewski A, Trussell J, Westhoff C.
    Eur J Contracept Reprod Health Care; 2013 Jun; 18(3):143-7. PubMed ID: 23578274
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Yasmin and venous thromboembolism: new case reports.
    López M, Vayá A, Martínez Triguero ML, Contreras MT, Todolí J, Ricart A, Laiz B.
    Clin Hemorheol Microcirc; 2009 Jun; 42(1):65-9. PubMed ID: 19363241
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Hormonal contraceptives and venous thromboembolism: an epidemiological update.
    Plu-Bureau G, Maitrot-Mantelet L, Hugon-Rodin J, Canonico M.
    Best Pract Res Clin Endocrinol Metab; 2013 Feb; 27(1):25-34. PubMed ID: 23384743
    [Abstract] [Full Text] [Related]

  • 30. Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives.
    Quehenberger P, Loner U, Kapiotis S, Handler S, Schneider B, Huber J, Speiser W.
    Thromb Haemost; 1996 Nov; 76(5):729-34. PubMed ID: 8950781
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. A review of post-marketing safety and surveillance data for oral contraceptives containing norgestimate and ethinyl estradiol.
    Lippman JS, Shangold GA.
    Int J Fertil Womens Med; 1997 Nov; 42(4):230-9. PubMed ID: 9309456
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Combined hormonal contraceptive use among women with known dyslipidemias: a systematic review of critical safety outcomes.
    Dragoman M, Curtis KM, Gaffield ME.
    Contraception; 2016 Sep; 94(3):280-7. PubMed ID: 26272309
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.